Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Neuroimaging to assess safety and efficacy of AD therapies.

Hill D.

Expert Opin Investig Drugs. 2010 Jan;19(1):23-6. doi: 10.1517/13543780903381320.

PMID:
19947893
2.

Applications of neuroimaging to disease-modification trials in Alzheimer's disease.

Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS; Alzheimer's Disease Neuroimaging Initiative.

Behav Neurol. 2009;21(1):129-36. doi: 10.3233/BEN-2009-0241. Review.

3.

The role of positron emission tomography imaging of beta-amyloid in patients with Alzheimer's disease.

Xiong KL, Yang QW, Gong SG, Zhang WG.

Nucl Med Commun. 2010 Jan;31(1):4-11. Review.

PMID:
19972633
4.

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography.

Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, Bergström M, Hyman BT, Långström B, Mathis CA.

Neuroimaging Clin N Am. 2003 Nov;13(4):781-9, ix. Review.

PMID:
15024961
5.

[Pre-symptomatic detection of Alzheimer's disease and mild cognitive impairment].

Arai H.

Rinsho Shinkeigaku. 2009 Nov;49(11):838-40. Review. Japanese.

PMID:
20030225
6.

Neuroimaging in Alzheimer's disease: relevance for treatment.

van Dyck CH.

Curr Psychiatry Rep. 2001 Feb;3(1):13-9. Review.

PMID:
11177754
7.

Neuroimaging outcomes for clinical trials.

Frisoni GB, Caroli A.

J Nutr Health Aging. 2007 Jul-Aug;11(4):348-52. Review.

PMID:
17653497
8.

Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease.

Matthews B, Siemers ER, Mozley PD.

Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):146-59. Review.

PMID:
12611744
9.

Amyloid plaque imaging in vivo: current achievement and future prospects.

Nordberg A.

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S46-50. doi: 10.1007/s00259-007-0700-2. Review.

PMID:
18188557
10.

Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development.

Pupi A, Mosconi L, Nobili FM, Sorbi S.

Mol Imaging Biol. 2005 Jan-Feb;7(1):59-68. Review.

PMID:
15912277
11.

[Molecular imaging of beta-amyloid plaques in the brain].

Ono M.

Brain Nerve. 2007 Mar;59(3):233-40. Review. Japanese.

PMID:
17370649
13.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
14.

Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.

Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA.

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S29-36. doi: 10.1016/j.jalz.2007.10.004. Epub 2007 Dec 21. Review.

PMID:
18631997
15.

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease.

Villemagne VL, Rowe CC, Macfarlane S, Novakovic KE, Masters CL.

J Clin Neurosci. 2005 Apr;12(3):221-30. Review.

PMID:
15851069
16.

[PET and SPECT investigations in Alzheimer's disease].

Asenbaum S.

Radiologe. 2003 Jul;43(7):521-30. Epub 2003 Jun 25. Review. German.

PMID:
12955214
17.
18.

Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.

Henriksen G, Yousefi BH, Drzezga A, Wester HJ.

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S75-81. doi: 10.1007/s00259-007-0705-x. Review.

PMID:
18224319
19.

Imaging biomarkers and their role in dementia clinical trials.

Chertkow H, Black S.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S77-83. Review.

PMID:
17469688
20.

Imaging, subjective complaints, and MCI: 30 years before.

Galluzzi S, Frisoni GB.

J Nutr Health Aging. 2008 Jan;12(1):80S-3S. Review.

PMID:
18165851
Items per page

Supplemental Content

Write to the Help Desk